Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
Business

Aequus Announces Sandoz Contract Expires at End of the Year and Anticipates Health Canada Approval of Zimed® PF (Preservative-Free), The Canadian Business Journal

VANCOUVER, British Columbia, November 29, 2022 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) today announced the launch of tacrolimus immediate release (immunosuppressive (“Tacrolimus IR”) with Sandoz Canada Inc. (“Sandoz”) and public relationsVistitan™ (bimatoprost 0.03% ophthalmic solution), effective December 31, 2022. In addition, Aequus will receive a “Notice of Compliance” from Health Canada for the launch of Zimed.® PF (Bimatoprost 0.03% Eye Drops) is the first “preservative-free” bimatoprost eye drop for patients with open-angle glaucoma or ocular hypertension. Health Canada approval is expected by the end of 2022.

Sandoz’s commercial collaboration began nearly seven years ago, public relationsVistitan™ and Tacrolimus IR. Aequus has deployed two dedicated national sales teams to facilitate rapid adoption of both products. Aequus achieves approximately 20% CAGR over his four years with Sandoz Tacrolimus IR brand through targeted awareness, value-added services and customized support for stakeholders in both states and transplant centers Did. public relationsVistitan™ is a prostaglandin for lowering IOP in patients with open-angle glaucoma or ocular hypertension. An experienced ophthalmic sales force, targeted digital marketing services, and strong relationships with Sandoz and the Canadian ophthalmic community have enabled Aequus to achieve consistent growth in the highly competitive Canadian market.

“With the expiry of our promotional services agreement, we aim to focus on licensed products with higher revenue potential, rather than third-party products, so we can move our business to the next level. Our Marketing Team We are proud to collaborate with Sandoz on the two products launched by Equus, demonstrating our ability to promote and grow specialty brands in critical early-stage market penetration.” fires a Jimed® As we continue to expand our commercial capabilities in PF, new therapeutic areas and new channels, we are optimistic that we will be able to add value to our new partners, Canadian physicians and patients. “

Aequus CEO and Chairman Doug Janzen said: We wish them the best of luck and hope we can work together again in the future. “

Health Canada approval pending Jimed®Canadian preservative-free bimatoprost (IOP lowering/glaucoma)

Aequus Pharma expects to obtain Health Canada approval for Zimed by December 31, 2022.® PF in multiple dose format.Jimed® PF offers eye care professionals and patients a new treatment option for open-angle glaucoma and ocular hypertension. Grant Larsen, his CCO at Aequus Pharma, said: “We look forward to working with Medicom Healthcare to launch this product in 2023.”

Doug Janzen added:® PF product and revenue potential for Aequus. Zimed takes several quarters to launch and build® PF sales are expected to eventually exceed previous earnings from sand products. The final payment from Sandoz is expected to be received in the first quarter of 2023. During the launch period, our revenue will be impacted, so as before, we will personally fund his Aequus as needed. “

About AEQUUS PHARMACEUTICALS INC.

Aequus Pharmaceuticals Inc. (TSX-V: AQSOTCQB: AQSZF) is a specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus is expanding its sales and marketing activities to include several commercial ophthalmic products. Aequus plans to build its Canadian commercial platform through the launch of additional products created internally or brought in through acquisitions or licenses, while remaining focused on highly specialized therapeutic areas. . For more information, visit his website at: www.aequspharma.ca.

Disclaimer of forward-looking statements

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities laws (collectively, “forward-looking statements”), which may include historical information. may not be based on actual facts. Expressions such as “may,” “plan,” “plan,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and “may.” . Forward-looking statements are necessarily based on estimates and assumptions made by the Company in the light of historical trends, current conditions, experience and perception of expected future developments, and factors it considers appropriate. Based on Forward-looking statements used herein include, but are not limited to, statements related to: Regulatory approval of Zimed® PF in the anticipated timing contemplated herein. Future projected or predicted growth trends. our ability to secure potential partners to further grow our product portfolio; Such statements reflect the Company’s current views regarding future events, are subject to risks and uncertainties and, although deemed reasonable by Aequs, are inherently important business, economic, competitive, political, and social uncertainties and contingencies; A number of factors could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. In making the forward-looking statements contained in this release, we make a number of important assumptions. general business and economic conditions; our ability to successfully license or sell our current products and license new products; the assumption that existing good relationships between us and third parties will be maintained; the availability of financing on reasonable terms; the company’s ability to attract and retain skilled staff; market competition; products and technologies offered by our competitors; Impact of coronavirus (COVID-19) on our business. Our Ability to Protect Our Patents and Proprietary Rights. In evaluating forward-looking statements, current and prospective shareholders should consider various factors described under the heading “Risk Factors” in this document and in the Company’s Annual Information Form dated June 30, 2022. must be considered specifically. SEDAR website www.sedar.com, and as disclosed from time to time in Aequus’ SEDAR profile. If one or more of these risks or uncertainties, or risks not currently known to us, materialize, or if the assumptions underlying these forward-looking statements prove to be incorrect; Actual results may differ materially from those stated herein. These forward-looking statements are made as of the date of this release and we do not intend to update these forward-looking statements except as required by applicable securities laws. , nor is it obligated to do so. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to place undue reliance on forward-looking statements.

Neither TSX Venture Exchange nor its regulated service providers (as those terms are defined in the TSX Venture Exchange Policy) are responsible for the adequacy or accuracy of this news release.

public relationsVistitan™ is a trademark owned or used by Sandoz Canada Inc. under license.

contact address:

Equus Investor Relations
Email: [email protected]
Phone: 604-336-7906


CBJ Newsmaker

Aequus Announces Sandoz Contract Expires at End of the Year and Anticipates Health Canada Approval of Zimed® PF (Preservative-Free), The Canadian Business Journal

Source link Aequus Announces Sandoz Contract Expires at End of the Year and Anticipates Health Canada Approval of Zimed® PF (Preservative-Free), The Canadian Business Journal

Related Articles

Back to top button